Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus POLMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus POLMON.
BRONKAID MIST vs POLMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Category C
Category C
Bronchodilator
Bronchodilator